ZUNVEYL
What it isOral galantamine prodrug yielding cholinesterase inhibition; symptomatic treatment of Alzheimer dementia.
Why this oneIts prodrug design reduces direct intestinal exposure while preserving galantamine’s central action.
What limits itBradycardia, syncope, nausea, and weight loss remain possible; benefit is symptomatic and fades when treatment stops.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Mild-to-moderate dementia of the Alzheimer's type | Adult | 5 mg BID | 10 mg BID after ≥4 weeks | 15 mg BID |
Titration Wait a minimum of 4 weeks at each dose level before increasing
Renal CrCl 9-59 mL/min: do not exceed 10 mg BID; CrCl <9: not recommended
Hepatic Moderate (Child-Pugh 7-9): do not exceed 10 mg BID; severe (10-15): not recommended; no adjustment for mild
Pregnancy No adequate human data; animal developmental toxicity (skeletal variations, decreased pup growth)
Lactation No human data on benzgalantamine or galantamine in milk
NO BOXED WARNINGS
Principal riskBradycardia; benefit is symptomatic only

Open Benzgalantamine in the interactive console ↗

